Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Levetiracetam in Chronic Neuropathic Pain Following Spinal Cord Injury

This study has been completed.
Sponsor:
Collaborator:
UCB NORDIC A/S
Information provided by:
Danish Pain Research Center
ClinicalTrials.gov Identifier:
NCT00252954
First received: November 14, 2005
Last updated: August 19, 2009
Last verified: August 2009
  Purpose

Purpose: To evaluate the efficacy and safety of levetiracetam on chronic neuropathic pain after spinal cord injury, and to examine its effect on spasms and evoked pain.


Condition Intervention Phase
Injuries, Spinal Cord
Pain
Drug: Levetiracetam
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Levetiracetam on Chronic Neuropathic Pain Following Spinal Cord Injury: a Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study

Resource links provided by NLM:


Further study details as provided by Danish Pain Research Center:

Primary Outcome Measures:
  • Change in median pain intensity (measured daily on a 10 point NRS) of spontaneous pain from baseline week to last week of treatment. [ Time Frame: Last week of each 5-week treatment period ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Spasms and spasticity; pain relief for total, at- and below-level pain; evoked pain; escape medication; NPSI; predictive value of the presence of evoked pain; Global impression of change; sleep disturbance. [ Time Frame: Last day of each 5-week treatment period ] [ Designated as safety issue: No ]

Enrollment: 36
Study Start Date: November 2005
Study Completion Date: December 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1 Drug: Levetiracetam
Tablets 2000-3000 mg per day

Detailed Description:

Study design: Randomized double-blind cross-over study of levetiracetam (Keppra) against corresponding placebo with a 1 week baseline period followed by 2 x 5 weeks treatment periods separated by a 1 week wash-out period.

Methodology: Levetiracetam and corresponding placebo is gradually increased during two weeks from 500 mg x 2 daily to 1500 mg x 2 daily (1000 mg x 2 daily is allowed if 1500 mg x 2 is not tolerated), and kept on that dose for three weeks.

The study will be monitored by the GCP units of Aarhus and Copenhagen University.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. age 18 or more
  • 2. neuropathic pain (that have lasted at least 3 month) after a spinal cord injury with a pain intensity of at least 4 on a 0-10 point numeric rating scale

Exclusion Criteria:

  • 1. pregnancy or lactation
  • 2. allergy to levetiracetam
  • 3. alcohol or substance abuse, mental disease, epilepsy, depression and psychiatric disorders, severe liver disease, decreased kidney function, and known concomitant cerebral damage
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00252954

Locations
Denmark
Danish Pain Research Center, Aarhus University Hospital
Aarhus, Denmark, 8000
Clinic for Spinal Cord Injuries, Rigshospitalet
Hornbaek, Denmark, 3100
The Spinal Cord Unit, Dept of Rheumatology
Viborg, Denmark, 8800
Sponsors and Collaborators
Danish Pain Research Center
UCB NORDIC A/S
Investigators
Principal Investigator: Nanna B Finnerup, MD Aarhus University Hospital
  More Information

Additional Information:
No publications provided by Danish Pain Research Center

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Nanna Brix Finnerup, Danish Pain Research Center
ClinicalTrials.gov Identifier: NCT00252954     History of Changes
Other Study ID Numbers: LEV-2005
Study First Received: November 14, 2005
Last Updated: August 19, 2009
Health Authority: Denmark: Danish Medicines Agency

Keywords provided by Danish Pain Research Center:
Spinal cord injury
Neuropathic pain
Spasms

Additional relevant MeSH terms:
Neuralgia
Spinal Cord Injuries
Spinal Injuries
Back Injuries
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Neuromuscular Diseases
Pain
Peripheral Nervous System Diseases
Signs and Symptoms
Spinal Cord Diseases
Trauma, Nervous System
Wounds and Injuries
Etiracetam
Piracetam
Anticonvulsants
Central Nervous System Agents
Neuroprotective Agents
Nootropic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014